Becton Dickinson (NYSE: BDX) reported first-quarter fiscal 2026 adjusted earnings of $2.91 per share, surpassing the consensus estimate, with sales slightly above expectations. However, the company lowered its fiscal 2026 adjusted earnings guidance significantly, from $14.75-$15.05 per share to $12.35-$12.65 per share, in anticipation of the separation of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation (NYSE: WAT). The Benzinga Edge Scorecard rates the company as “Weak” in Value due to trading at a premium, and “Neutral” in Quality, indicating a healthy balance sheet.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Becton Dickinson Slashes Profit Outlook Post-Spinoff
Becton Dickinson (NYSE: BDX) reported first-quarter fiscal 2026 adjusted earnings of $2.91 per share, surpassing the consensus estimate, with sales slightly above expectations. However, the company lowered its fiscal 2026 adjusted earnings guidance significantly, from $14.75-$15.05 per share to $12.35-$12.65 per share, in anticipation of the separation of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation (NYSE: WAT). The Benzinga Edge Scorecard rates the company as “Weak” in Value due to trading at a premium, and “Neutral” in Quality, indicating a healthy balance sheet.